Cited by 704Lipoproteins and Cardiovascular HealthGenetic Associations and EpidemiologyNutrition, Genetics, and Disease

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

Open access

Mega, Jessica L, Stitziel, Nathan O, Smith, J Gustav, Chasman, Daniel I, Caulfield, Mark J, Devlin, James J, Nordio, Francesco, Hyde, Craig L, Cannon, Christopher P, Sacks, Frank M, Poulter, Neil R, Sever, Peter S, Ridker, Paul M, Braunwald, Eugene, Melander, Olle, Kathiresan, Sekar, Sabatine, Marc S·2015·The Lancet

DOI 10.1016/s0140-6736(14)61730-xPMC PMC4608367

Open this paper in CoChat — free account

Abstract

Background Genetic variants have been associated with the risk of coronary heart disease. In this study, we tested whether or not a composite of these variants could ascertain the risk of both incident and recurrent coronary heart disease events and identify those individuals who derive greater clinical benefit from statin therapy.Methods A community-based cohort study (the Malmo Diet and Cancer Study) and four randomised controlled trials of both primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PROVE IT-TIMI 22) with statin therapy, comprising a total of 48,421 individuals and 3477 events, were included in these analyses. We studied the association of a genetic risk score based on 27 genetic variants with incident or recurrent coronary heart disease, adjusting for traditional clinical risk factors. We then investigated the relative and absolute risk reductions in coronary heart disease events with statin therapy stratified by genetic risk. We combined data from the different studies using a meta-analysis.Findings When individuals were divided into low (quintile 1), intermediate (quintiles 2-4), and high (quintile 5) genetic risk categories, a significant gradient in risk for incident or recurrent coronary heart disease was shown. Compared with the low genetic risk category, the multivariable-adjusted hazard ratio for coronary heart disease for the intermediate genetic risk category was 1·34 (95% CI 1·22-1·47, p<0·0001) and that for the high genetic risk category was 1·72 (1·55-1·92, p<0·0001). In terms of the benefit of statin therapy in the four randomised trials, we noted a significant gradient (p=0·0277) of increasing relative risk reductions across the low (13%), intermediate (29%), and high (48%) genetic risk categories. Similarly, we noted greater absolute risk reductions in those individuals in higher genetic risk categories (p=0·0101), resulting in a roughly threefold decrease in the number needed to treat to prevent one coronary heart disease event in the primary prevention trials. Specifically, in the primary prevention trials, the number needed to treat to prevent one such event in 10 years was 66 in people at low genetic risk, 42 in those at intermediate genetic risk, and 25 in those at high genetic risk in JUPITER, and 57, 47, and 20, respectively, in ASCOT.Interpretation A genetic risk score identified individuals at increased risk for both incident and recurrent coronary heart disease events. People with the highest burden of genetic risk derived the largest relative and absolute clinical benefit from statin therapy.Funding National Institutes of Health.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)61730-x

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Reduced dietary salt for the prevention of cardiovascular disease
Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L., & Ebrahim, S. B. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009217.pub2 · Cited by 311
Retracted
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citation
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citation
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Self-citation
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citation
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934

Show all 46 references

Sorted by citations

Items 201–300 of 704

Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering
Marston, N., Kamanu, F., Melloni, G. E. M., Schnitzler, G. R., Hakim, A., Ma, X. R., Kang, H. Y., Chasman, D. I., Giugliano, R. P., Ellinor, P. T., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03533-w · Cited by 29
Self-citation
Association of six CpG-SNPs in the inflammation-related genes with coronary heart disease
Chen, X., Chen, X., Xu, Y., Yang, W. E., Wu, N., Ye, H., Yang, J. Y., Hong, Q., Xin, Y., Yang, M. Q., et al. (2016) · Human Genomics · doi:10.1186/s40246-016-0067-1 · Cited by 29
Association analysis of rs1049255 and rs4673 transitions in p22phox gene with coronary artery disease: A case-control study and a computational analysis
Mazaheri, M., Karimian, M., Behjati, M., Raygan, F., & Colagar, A. H. (2017) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-017-1601-4 · Cited by 29
Coronary Heart Disease Genetic Risk Score Predicts Cardiovascular Disease Risk in Men, Not Women
Hajek, C. A., Guo, X., Yao, J., Hai, Y., Johnson, W. C., Wood, A. C., Post, W. S., Psaty, B. M., Taylor, K. D., & Rotter, J. I. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002324 · Cited by 29
Using a genetic risk score to calculate the optimal age for an individual to undergo coronary artery calcium screening
Severance, L. M., Contijoch, F. J., Carter, H. K., Fan, C. C., Seibert, T. M., Dale, A. M., & McVeigh, E. R. (2019) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2019.05.005 · Cited by 29
Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study
Bacquer, D. D., Smedt, D. D., Reiner, Ž., Tokgözoğlu, L. S., Clays, E., Kotseva, K., Rydén, L., Wood, D., & Backer, G. D. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319874898 · Cited by 29
Polygenic risk scores for genetic counseling in psychiatry: Lessons learned from other fields of medicine
Eeltink, E., van der Horst, M. Z., Zinkstok, J., Aalfs, C. M., & Luykx, J. J. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.11.021 · Cited by 28
What Causes Premature Coronary Artery Disease?
Le, A., Peng, H., Golinsky, D., Scipio, M. D., Lali, R., & Paré, G. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01200-y · Cited by 33
Translating polygenic risk scores for clinical use by estimating the confidence bounds of risk prediction
Sun, J., Wang, Y., Folkersen, L., Borné, Y., Amlien, I. K., Buil, A., Orho‐Melander, M., Børglum, A. D., HOUGAARD, D. M., Lotta, L. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25014-7 · Cited by 27
Self-citation
Effectiveness and feasibility of cardiovascular disease personalized prevention on high polygenic risk score subjects: a randomized controlled pilot study
Viigimaa, M., Jürisson, M., Pisarev, H., Kalda, R., Alavere, H., Irs, A., Saar, A., Fischer, K., Läll, K., Kruuv-Käo, K., et al. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac079 · Cited by 24
Genetic Risk Scores Predict Recurrence of Acute Coronary Syndrome
Vaara, S. M., Tikkanen, E., Parkkonen, O., Lokki, M., Ripatti, S., Perola, M., Nieminen, M. S., & Sinisalo, J. P. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001271 · Cited by 27
Monogenic and Polygenic Models of Coronary Artery Disease
Muse, E. D., Chen, S.-F., & Torkamani, A. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01540-0 · Cited by 27
JCS/JCC/JSPCCS 2024 Guideline on Genetic Testing and Counseling in Cardiovascular Disease
Imai, Y., Kusano, K., Aiba, T., Ako, J., Asano, Y., Harada‐Shiba, M., Kataoka, M., Kosho, T., Kubo, T., Matsumura, T., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0926 · Cited by 34
Genome-Wide Association Studies of Coronary Artery Disease: Recent Progress and Challenges Ahead
Clarke, S. L., & Assimes, T. L. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0748-4 · Cited by 27
Cardiovascular risk factor mediation of the effects of education and Genetic Risk Score on cardiovascular disease: a prospective observational cohort study of the Framingham Heart Study
Powell, K., Stephens, S., & Stephens, A. S. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045210 · Cited by 29
Moving Toward the Next Paradigm for Cardiovascular Prevention
Robinson, J. G., & Ray, K. K. (2016) · Circulation · doi:10.1161/circulationaha.116.022134 · Cited by 27
Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease
Tada, H., Kawashiri, M., & Yamagishi, M. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17002 · Cited by 27
LDL-cholesterol control in the primary prevention of cardiovascular diseases: An expert opinion for clinicians and health professionals
Poli, A., Catapano, A. L., Corsini, A., Manzato, E., Werba, J. P., Catena, G., Cetin, I., Cicero, A. F. G., Cignarella, A., Colivicchi, F., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.10.001 · Cited by 27
Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation
Gagelmann, N., Badbaran, A., Salit, R. B., Schroeder, T. A., Gurnari, C., Pagliuca, S., Panagiota, V., Rautenberg, C., Cassinat, B., Thol, F. R., et al. (2023) · Blood · doi:10.1182/blood.2023019630 · Cited by 27
EraSOR: a software tool to eliminate inflation caused by sample overlap in polygenic score analyses
Choi, S. W., Mak, T. S. H., Hoggart, C., & O’Reilly, P. F. (2022) · GigaScience · doi:10.1093/gigascience/giad043 · Cited by 26
Discriminating bipolar depression from major depressive disorder with polygenic risk scores
Liebers, D. T., Pirooznia, M., Ganna, A., (BiGS), B. G. S., & Goes, F. S. (2020) · Psychological Medicine · doi:10.1017/s003329172000015x · Cited by 29
Inflammation-Related Risk Loci in Genome-Wide Association Studies of Coronary Artery Disease
Mauersberger, C., Schunkert, H., & Sager, H. B. (2021) · Cells · doi:10.3390/cells10020440 · Cited by 27
GWAS breakthroughs: Mapping the journey from one locus to 393 significant coronary artery disease associations
Aherrahrou, R., Reinberger, T., Hashmi, S., & Erdmann, J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae161 · Cited by 25
Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts
Dagli-Hernandez, C., Zhou, Y., Lauschke, V. M., Genvigir, F. D. V., Hirata, T. D. C., Hirata, M. H., & Hirata, R. D. C. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00319-y · Cited by 25
Lessons learned from the eMERGE Network: balancing genomics in discovery and practice
(2020) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2020.100018 · Cited by 27
Genetic risk score enhances the risk prediction of severe obesity in adult survivors of childhood cancer
Sapkota, Y., Qiu, W., Dixon, S. B., Wilson, C. L., Wang, Z., Zhang, J., Leisenring, W. M., Chow, E. J., Bhatia, S., Armstrong, G. T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01902-3 · Cited by 25
HNF1A regulates colorectal cancer progression and drug resistance as a downstream of POU5F1
Fujino, S., Miyoshi, N., Ito, A., Yasui, M., Matsuda, C., Ohue, M., Uemura, M., Mizushima, T., Doki, Y., & Eguchi, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-89126-2 · Cited by 25
Polygenic Risk Score to Identify Subclinical Coronary Heart Disease Risk in Young Adults
Wells, Q. S., Bagheri, M., Aday, A. W., Gupta, D. K., Shaffer, C. M., Wei, W., Vaitinadin, N. S., Khan, S. S., Greenland, P., Wang, T. J., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003341 · Cited by 26
Human Genetics Society of Australasia Position Statement: Use of Polygenic Scores in Clinical Practice and Population Health
Young, M., Yanes, T., Cust, A. E., Dunlop, K. L. A., Limb, S., Newson, A. J., Purvis, R., Thiyagarajan, L., Scott, R. J., Verma, K. P., et al. (2023) · Twin Research and Human Genetics · doi:10.1017/thg.2023.10 · Cited by 24
Adherence to a healthy lifestyle, genetic susceptibility to abdominal obesity, cardiometabolic risk markers, and risk of coronary heart disease
Wang, M., Yeung, S. L. A., Luo, S., Jang, H., Ho, H. S., Sharp, S. J., Wijndaele, K., Brage, S., Wareham, N. J., & Kim, Y. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.08.002 · Cited by 24
Long-term follow-up of lipid-lowering trials
Packard, C. J., & Ford, I. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000230 · Cited by 24
MicroRNA-126/stromal cell-derived factor 1/C-X-C chemokine receptor type 7 signaling pathway promotes post-stroke angiogenesis of endothelial progenitor cell transplantation
Shan, C., & Ma, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8513 · Cited by 24
Prediction and management of CAD risk based on genetic stratification
Roberts, R., Campillo, A., & Schmitt, M. E. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.08.006 · Cited by 26
Genetic architecture of cardiometabolic risks in people living with HIV
Cheng, H. M., Sewda, A., Márquez‐Luna, C., White, S. R., Whitney, B. M., Williams-Nguyen, J. S., Nance, R. M., Lee, W. J., Kitahata, M. M., Saag, M. S., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01762-z · Cited by 26
The Inherited Basis of Coronary Artery Disease
Schunkert, H., Natarajan, P., & Samani, N. J. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2405153 · Cited by 23
Exploring the mechanism of Shengmai Yin for coronary heart disease based on systematic pharmacology and chemoinformatics
Jiang, Y. J., He, Q., Zhang, T., Xiang, W., Long, Z., & Wu, S. (2020) · Bioscience Reports · doi:10.1042/bsr20200286 · Cited by 23
Risk Stratification and Clinical Utility of Polygenic Risk Scores in Ophthalmology
Qassim, A., Souzeau, E., Hollitt, G. L., Hassall, M., Siggs, O. M., & Craig, J. E. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.6.14 · Cited by 24
The positive end of the polygenic score distribution for ADHD: a low risk or a protective factor?
Li, J. J. (2019) · Psychological Medicine · doi:10.1017/s0033291719003039 · Cited by 24
Utility of a genetic risk score to predict recurrent cardiovascular events 1 year after an acute coronary syndrome: A pooled analysis of the RISCA, PRAXY, and TRIUMPH cohorts
Labos, C., Martinez, S. C., Wang, R. H. L., Lenzini, P. A., Pilote, L., Bogaty, P. M., Brophy, J. M., Engert, J. C., Cresci, S., & Thanassoulis, G. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.029 · Cited by 21
Polygenic Background Modifies Risk of Coronary Artery Disease Among Individuals With Heterozygous Familial Hypercholesterolemia
Reeskamp, L. F., Shim, I., Dron, J. S., Ibrahim, S., Tromp, T. R., Fahed, A. C., Patel, A. P., Hutten, B. A., Stroes, E. S. G., Hovingh, G. K., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100662 · Cited by 21
Artificial Intelligence for Risk Assessment on Primary Prevention of Coronary Artery Disease
Chen, S., Loguercio, S., Chen, K., Lee, S. E., Park, J., Liu, S., Sadaei, H. J., & Torkamani, A. (2023) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-023-00731-4 · Cited by 26
Pharmacogenomics polygenic risk score: Ready or not for prime time?
Singh, S., Stocco, G., Theken, K. N., Dickson, A. L., Feng, Q., Karnes, J. H., Mosley, J. D., & Rouby, N. M. E. (2024) · Clinical and Translational Science · doi:10.1111/cts.13893 · Cited by 25
Triglyceride glucose-waist circumference as a predictor of mortality and subtypes of cardiovascular disease: a systematic review and meta-analysis
Rad, M. R., Dabaghi, G. G., Sadri, H., Darouei, B., Amani‐Beni, R., & Mazaheri‐Tehrani, S. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01616-9 · Cited by 22
A genetic risk score predicts cardiovascular events in patients with stable coronary artery disease
Christiansen, M. K., Nyegaard, M., Larsen, S. B., Grove, E. L., Würtz, M., Neergaard‐Petersen, S., Hvas, A., Jensen, H. K., & Kristensen, S. D. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.04.045 · Cited by 21
Genetic Approaches to the Study of Gene Variants and Their Impact on the Pathophysiology of Type 2 Diabetes
Szabó, M. I., Máté, B., Csép, K., & Benedek, T. (2017) · Biochemical Genetics · doi:10.1007/s10528-017-9827-4 · Cited by 23
Taking the next steps to implement polygenic risk scoring for improved risk stratification and primary prevention of coronary artery disease
Figtree, G. A., Vernon, S. T., & Nicholls, S. J. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa030 · Cited by 22
Polygenic risk scores: how much do they add?
Christoffersen, M., & Tybjærg‐Hansen, A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000759 · Cited by 22
Urinary metals as influencing factors of coronary heart disease among a population in Guangzhou, China
Liu, X., Zhang, D., Wu, X., Tu, J., Gong, C., Li, Y., Cui, W., Chen, J., & Lu, S. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113746 · Cited by 22
Are polygenic risk scores ready for the cancer clinic?—a perspective
Klein, R. J., & Gumus, Z. H. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-698 · Cited by 21
Prediction of Coronary Artery Disease and Major Adverse Cardiovascular Events Using Clinical and Genetic Risk Scores for Cardiovascular Risk Factors
Ramírez, J., van Duijvenboden, S., Young, W. J., Tinker, A., Lambiase, P. D., Orini, M., & Munroe, P. B. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003441 · Cited by 23
Metabolic profiling of smoking, associations with type 2 diabetes and interaction with genetic susceptibility
Wei, Y., Hägg, S., Mak, J. K. L., Tuomilehto, J., Zhan, Y., & Carlsson, S. (2024) · European Journal of Epidemiology · doi:10.1007/s10654-024-01117-5 · Cited by 24
Novel Biomarkers for Cardiovascular Risk Assessment: Current Status and Future Directions
MacNamara, J. P., Eapen, D. J., Quyyumi, A. A., & Sperling, L. S. (2015) · Future Cardiology · doi:10.2217/fca.15.39 · Cited by 23
Family history and polygenic risk of cardiovascular disease: Independent factors associated with secondary cardiovascular events in patients undergoing carotid endarterectomy
Timmerman, N., de Kleijn, D. P. V., de Borst, G. J., den Ruijter, H. M., Asselbergs, F. W., Pasterkamp, G., Haitjema, S., & van der Laan, S. W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.04.013 · Cited by 22
Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis
Aldi, S., Matic, L. P., Hamm, G. R., van Keulen, D., Tempel, D., Holmstrøm, K., Szwajda, A., Nielsen, B. S., Emilsson, V., Ait-Belkacem, R., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.05.003 · Cited by 21
Smoking Status and Type 2 Diabetes, and Cardiovascular Disease: A Comprehensive Analysis of Shared Genetic Etiology and Causal Relationship
Chi, Y., Wang, X., Jia, J., & Huang, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.809445 · Cited by 22
Genetic and modifiable risk factors combine multiplicatively in common disease
Pang, S., Yengo, L., Nelson, C. P., Bourier, F. J., Zeng, L., Li, L., Kessler, T., Erdmann, J., Mägi, R., Läll, K., et al. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02081-4 · Cited by 21
Combining machine learning with Cox models to identify predictors for incident post-menopausal breast cancer in the UK Biobank
Liu, X., Morelli, D., Littlejohns, T. J., Clifton, D. A., & Clifton, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-36214-0 · Cited by 21
Common genetic risk factors for coronary artery disease: new opportunities for prevention?
Hamrefors, V. (2015) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12289 · Cited by 22
Polygenic Risk Is Associated With Long-Term Coronary Plaque Progression and High-Risk Plaque
Nurmohamed, N. S., Shim, I., Gaillard, E. L., Ibrahim, S., Bom, M. J., Earls, J. P., Min, J. K., Planken, R. N., Choi, A. D., Natarajan, P., et al. (2024) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2024.06.015 · Cited by 22
New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease
Katzmann, J. L., & Laufs, U. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1159-z · Cited by 19
How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?
Hadley, T. D., Agha, A. M., & Ballantyne, C. M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00915-6 · Cited by 21
Diet Associated with Inflammation and Alzheimer’s Disease
Vasefi, M., Hudson, M., & Ghaboolian-Zare, E. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190152 · Cited by 21
A multi-locus genetic risk score for abdominal aortic aneurysm
Ye, Z., Austin, E. E., Schaid, D. J., & Kullo, I. J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.031 · Cited by 19
A polygenic-score-based approach for identification of gene-drug interactions stratifying breast cancer risk.
Marderstein, A. R., Kulm, S., Peng, C., Tamimi, R. M., Clark, A. G., & Elemento, O. (2021) · American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.07.008 · Cited by 15
Response to Sodium Channel blocking Antiseizure medications and coding polymorphisms of Sodium Channel genes in Taiwanese epilepsy patients
Lin, C., Ho, C.-J., Lu, Y., & Tsai, M. (2021) · BMC Neurology · doi:10.1186/s12883-021-02395-2 · Cited by 19
Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real‐World Population
Oni‐Orisan, A., Haldar, T., Cayabyab, M. A. S., Ranatunga, D. K., Hoffmann, T. J., Iribarren, C., Krauss, R. M., & RISCH, N. J. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2715 · Cited by 18
Exploring the challenges of and solutions to sharing personal genomic data for use in healthcare
Parvinen, L., Alamäki, A. V., Hallikainen, H., & Mäki, M. (2023) · Health Informatics Journal · doi:10.1177/14604582231152185 · Cited by 20
Role of non‐coding variants in cardiovascular disease
Heshmatzad, K., Naderi, N., Maleki, M., Abbasi, S., Ghasemi, S., Ashrafi, N., Fazelifar, A. F., Mahdavi, M., & Kalayinia, S. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17762 · Cited by 18
Screening potential prognostic biomarkers of long non-coding RNAs for predicting the risk of chronic kidney disease
Li, N., Cui, Y., Yin, M., & Liu, F. (2019) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20198333 · Cited by 19
Challenges of Precision Medicine for Atherosclerotic Cardiovascular Disease Based on Human Genome Information
Tada, H., Usui, S., Sakata, K., Takamura, M., & Kawashiri, M. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60087 · Cited by 19
Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?
Jacob, E. O., & Hegele, R. A. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01018-6 · Cited by 19
Meta-prediction of coronary artery disease risk
Chen, S., Lee, S. E., Sadaei, H. J., Park, J., Khattab, A., Chen, J., Hénégar, C., Wineinger, N. E., Muse, E. D., & Torkamani, A. (2025) · Nature Medicine · doi:10.1038/s41591-025-03648-0 · Cited by 19
Plasma signals of lung tumor promotion for molecular cancer prevention
Pandya, T., Zagorulya, M., Leung, M. M., Augustine, M., Liu, L., Leppä, A., Baruchel, U., Ng, S. W., Klockner, T., Mugabo, M., et al. (2026) · Cell · doi:10.1016/j.cell.2026.05.005 · Cited by 22
NLRP3 Inflammasome: a Novel Insight into Heart Failure
Wang, Y., Li, Y., Zhang, W., Yuan, Z., Lv, S., & Zhang, J. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10286-1 · Cited by 19
Sex-Specific Survival Bias and Interaction Modeling in Coronary Artery Disease Risk Prediction
Surakka, I. L., Wolford, B. N., Ritchie, S. C., Hornsby, W., Sutton, N. R., Gabrielsen, M. E., Skogholt, A. H., Thomas, L. F., Inouye, M., Hveem, K., et al. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.121.003542 · Cited by 20
Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases
Benincasa, G., Suades, R., Padró, T., Badimón, L., & Claudio Napoli, A. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad059 · Cited by 19
Contribution of Lipoprotein(a) to Polygenic Risk Prediction of Coronary Artery Disease: A Prospective UK Biobank Analysis
Manikpurage, H. D., Paulin, A., Girard, A. S., Eslami, A., Mathieu, P., Thériault, S., & Arsenault, B. J. (2023) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.123.004137 · Cited by 21
Population Impact & Efficiency of Benefit‐Targeted Versus Risk‐Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease
Pletcher, M. J., Pignone, M. P., Jarmul, J. A., Moran, A. E., Vittinghoff, E., & Newman, T. B. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004316 · Cited by 18
Metabolic Mediators of the Effects of Family History and Genetic Risk Score on Coronary Heart Disease—Findings From the Malmö Diet and Cancer Study
Fritz, J., Shiffman, D., Melander, O., Tada, H., & Ulmer, H. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005254 · Cited by 18
Self-citation
A decade of progress on the genetic basis of coronary artery disease. Practical insights for the internist
Girelli, D., Piubelli, C., Martinelli, N., Corrocher, R., & Olivieri, O. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.019 · Cited by 18
Genetic Markers for Coronary Artery Disease
Veljković, N., Zarić, B. L., Đorić, I., Obradovic, M. M., Sudar-Milovanovic, E. M., Radak, D. J., & Isenović, E. R. (2018) · Medicina · doi:10.3390/medicina54030036 · Cited by 18
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1114 · Cited by 19
Generalizability of “GWAS Hits” in Clinical Populations: Lessons from Childhood Cancer Survivors
Im, C., Qin, N., Wang, Z., Qiu, W., Howell, C. R., Sapkota, Y., Moon, W., Chemaitilly, W., Gibson, T. M., Mulrooney, D. A., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.08.014 · Cited by 19
Prospective association of a genetic risk score with major adverse cardiovascular events in patients with coronary artery disease
Zhao, C., Zhu, P., Shen, Q., & Jin, L. (2017) · Medicine · doi:10.1097/md.0000000000009473 · Cited by 18
Cardiovascular Family History Increases the Risk of Disease Recurrence After a First Myocardial Infarction
Wahrenberg, A., Kuja‐Halkola, R., Magnusson, P. K. E., Häbel, H., Warnqvist, A., Hambræus, K., Jernberg, T., & Svensson, P. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022264 · Cited by 22
Polygenic Risk Score Associates With Atherosclerotic Plaque Characteristics at Autopsy
Cornelissen, A., Gadhoke, N. V., Ryan, K. A., Hodonsky, C. J., Mitchell, R., Bihlmeyer, N. A., Duong, T., Chen, Z., Dikongue, A., Sakamoto, A., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319818 · Cited by 16
The Combined Effect of Polygenic Risk from FTO and ADRB2 Gene Variants, Odds of Obesity, and Post-Hipcref Diet Differences
Tan, P. Y., & Mitra, S. R. (2020) · Lifestyle Genomics · doi:10.1159/000505662 · Cited by 17
Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance
Trinder, M., & Brunham, L. R. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000737 · Cited by 17
Associations between polygenic risk of coronary artery disease and type 2 diabetes, lifestyle, and cardiovascular mortality: A prospective UK Biobank study
Yun, J., Jung, S., Shivakumar, M., Xiao, B., Khera, A. V., Park, W., Won, H., & Kim, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.919374 · Cited by 19
Cardiovascular Pharmacogenomics—Implications for Patients With CKD
Cavallari, L. H., & Mason, D. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2015.12.001 · Cited by 17
Advances in the treatment of dyslipidemia
Sabatine, M. S. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83gr.16001 · Cited by 17
Self-citation
Family or SNPs: what counts for hereditary risk of coronary artery disease?
Schunkert, H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv545 · Cited by 17
Polygenic risk, aspirin, and primary prevention of coronary artery disease
Yu, C., Natarajan, P., Patel, A. P., Bhatia, H. S., Khera, A. V., Neumann, F., Tsimikas, S., Wolfe, R. S., Nicholls, S. J., Reid, C. M., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae085 · Cited by 17
The GEnetic Syntax Score: a genetic risk assessment implementation tool grading the complexity of coronary artery disease—rationale and design of the GESS study
Vizirianakis, I. S., Chatzopoulou, F. M., Papazoglou, Α. S., Karagiannidis, E., Sofidis, G., Stalikas, N., Stefopoulos, C., Kyritsis, K., Mittas, N., Theodoroula, N. F., et al. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02092-5 · Cited by 16
Mutated CYP17A1 promotes atherosclerosis and early-onset coronary artery disease
Wu, T., Zheng, Y., Ma, X., Xiu, W., Yang, H.-T., Hou, X., Yang, Y., Chen, Y., Ma, Y.-T., & Xie, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01061-z · Cited by 16
Advances in the understanding of nuclear pore complexes in human diseases
Li, Y., Zhu, J., Zhai, F., Kong, L., Li, H., & Jin, X. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05881-5 · Cited by 16
Polygenic risk scores improve CAD risk prediction in individuals at borderline and intermediate clinical risk
Ratman, D., Tshiaba, P., Levin, M. G., Sun, J., Tunstall, T. S., Maier, R., Shah, P., Rabinowitz, M., Rader, D. J., Kumar, A., et al. (2025) · npj Cardiovascular Health · doi:10.1038/s44325-025-00049-7 · Cited by 16
Precision reproductive medicine: multigene panel testing for infertility risk assessment
Collins, S. C. (2017) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-017-0938-y · Cited by 16
An Outbreak of Polygenic Scores for Coronary Artery Disease
Rotter, J. I., & Lin, H. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.054 · Cited by 15
Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review
Song, S. H., & Byun, S. (2021) · Korean journal of urology · doi:10.4111/icu.20210124 · Cited by 16

Authors: Mega, J. L., Stitziel, N. O., Smith, J. G., Chasman, D. I., Caulfield, M. J., Devlin, J. J., Nordio, F., Hyde, C. L., Cannon, C. P., Sacks, F. M., Poulter, N. R., Sever, P. S., Ridker, P. M., Braunwald, E., Melander, O., Kathiresan, S., & Sabatine, M. S.
Affiliations: Brigham and Women's Hospital (US)
Washington University in St. Louis (US)
Broad Institute (US)
Queen Mary University of London (GB)
Quest Diagnostics (United States) (US)
Pfizer (United States) (US)
Imperial College London (GB)
Lund University (SE)
Corresponding author: Mega, Jessica L
Stitziel, Nathan O
ORCID: Mega, Jessica L
Stitziel, Nathan O
Chasman, Daniel I
Caulfield, Mark J
Hyde, Craig L
Cannon, Christopher P
Sacks, Frank M
Poulter, Neil R
Ridker, Paul M
Melander, Olle
Kathiresan, Sekar
Sabatine, Marc S
Venue: The Lancet
Publisher: Elsevier BV
Published: 2015-06
Volume: 385
Issue: 9984
Pages: 2264-2271
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(14)61730-x
PMC: PMC4608367
OpenAlex: W2171705978
Cited by: 704
References: 46
Citations by year: 2026: 40 · 2025: 48 · 2024: 51 · 2023: 69 · 2022: 78 · 2021: 83 · 2020: 78 · 2019: 59 · 2018: 62 · 2017: 53 · 2016: 57 · 2015: 25
FWCI: 12.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
Lund University Publications (Lund University) (submittedVersion)
Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
Funders: National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) (RC1 HL099634)
NIH and the NHLBI (grant K08 HL114642)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
Keywords: coronary artery disease, polygenic risk score, genetic variants, statin therapy, primary prevention, secondary prevention, number needed to treat, risk stratification, JUPITER trial, ASCOT trial, CARE trial, PROVE IT-TIMI 22, recurrent cardiovascular events, Malmö Diet and Cancer Study, cardiovascular risk prediction, treatment benefit stratification, LDL cholesterol lowering
MeSH terms: Coronary Disease, Humans, Primary Prevention, Recurrence, Treatment Outcome, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Secondary Prevention, Numbers Needed To Treat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks